Summary The evolution of in vitro bone marrow clonogenic leukaemic cells (CFU-L) drug sensitivity was studied in 23 patients with acute myeloid leukaemia treated with anthracycline and cytosine arbinoside (ara-C). In 12 patients tested before and after first induction treatment failure (interval: 6+4 weeks), the sensitivity remained stable for daunorubicin and showed little variation for ara-C. Among eleven patients tested before treatment and at first relapse (interval: 13+7 months), in vitro CFU-L sensitivity revealed no correlation between the two measurements, and a trend in decreased sensitivity to daunorubicin and ara-C. These findings suggest that induction failures could be related to factors other than simple selection of a resistant CFU-L subclone.
other patients. Two patients were treated with a phase II protocol (low dose ara-C or aclacinomycine) without success, and two patients did not receive subsequent chemotherapy.
Eleven patients (mean age: 55 + 13 years old, range: 22-69) with AML (2 M1, 3 M2, 3 M3 3 M4; 71% + 18 bone marrow leukaemic cells) were tested at diagnosis and at first relapse. These patients entered into CR after induction treatment including anthracycline (adriamycin: 2 cases; DNR: 9 cases) and ara-C at conventional dose ('AML5, 6' of'EORTC) . A consolidation course with the same drugs was administered in all cases. Maintenance treatment was alternation of amsacrine + HiDAC/amsacrine + 5 azacytidine (6 courses) in 4 cases, DNR + ara-C (6 courses) in 3 cases, 6 mercaptopurine + methotrexate orally and DNR + VCR ( x 6) in 2 cases, 6 thioguanine + ara-C + immunotherapy in one case, and HiDAC + amsacrine ('intensive consolidation' x 2) in one case. Relapse (74+ 16% bone marrow leukaemic cells) occurred after an average of 13+7 months (range: 5-30 months) following attainment of CR. Six patients achieved as second CR with DNR+ara-C (3 cases) or HiDAC+amsacrine (3 cases), 5 patients failed (2 deaths during treatment and 3 resistant cases).
Methods
Cell preparation Mononuclear cell suspensions were obtained from marrow aspirate by centrifugation using density 1077 MSL (Eurobio Lab.) .
T lymphocytes were depleted by a second centrifugation after sheep erythrocyte rosette formation as described by Minden et al. (1979) .
CFU-L assay Blast colony formation. The technique has been described previously (Marie et al., 1983) . Briefly, 2 x 104T-depleted cells in 0.1 ml alpha medium were plated with methyl cellulose (0.8%), 20% foetal calf serum (Flow Laboratories) and 10% PHA-LCM in 1 ml microwells (Titertek Lab.). Eight to 10 microwells were plated and incubated in a moist atmosphere with 6% carbon dioxide.
Aggregates >20 cells were counted at day 7 (plating efficiency 1, or PE1), and several colonies were pooled for May-Griinwald giemsa staining and detection of T cells if an unusual aspect of the colonies was noted.
Drug exposure According to in vivo drug pharmaco-kinetics during AML Br. J. Cancer (1988), 58, 570-574 protocols, the cells were exposed briefly to anthracycline and continuously to ara-C: T-depleted cells (3 x 106) were incubated in alpha medium containing 10% FCS for 30min with 10 7, 10 6 and 10 5M daunorubicin (DNR). The cells were pelleted, washed twice in large alpha medium excess and plated as before.
For ara-C, continuous exposure to 10-7, 10 -6 and 10-5M were tested, the drug being added just before plating.
A minimum of 4 microwells was counted at day 7 for each drug. Results were expressed as (i) number of surviving colonies, percentage of inhibition of CFU-L compared to controls without drugs (a minimum of 15 colonies per well in controls was required for results to be recorded); and (ii) dose inhibiting 50% of the CFU-L for ara-C (DI50) and 70% of the CFU-L for DNR (DI70), according to our previous data (Marie ct al., 1987) .
Statistics
The Mann-Whitney test was used to compare quantitative data, and linear regression analysis for comparison of results of replicate studies in each patient.
Results
Resisting patients (Table I) The cloning elfficiency (PEI) was stable in 7 patients and decreased in the 4 other cases.
The in vitro CFU-L drug sensitivity showed few variations when tested before treatment and at time of leukaemic regrowth: the level of CFU-L inhibition to DNR (30 min exposure, Figure 1 ) to 10 6M (55+410o and 56.6+36% respectively; r =0.8, P =0.006) and to 10 5M (76 + 31 and 79 + 39, -0.98, P =0.005) did not change. A significant increase (>1 log) in the DI0 (DNR) was observed only in 3/12 patients.
The CFU-L inhibition after continuous exposure to 10 5M ara-C was less stable than for DNR (Figure 2 ) in each patient (89+144% at induction and 79+210% at Ieukaemic regrowth; r=0.57, P=0.06 ). An increase of DI50 (ara-C) was observed in 3/12 patients.
Four patients were treated with a 'salvage' protocol including HiDAC and AMSA, and a CR obtained in 3 cases, despite in vitro CFU-L resistance to 10-5 M ara-C (equivalent to conventional doses) in one case (pt 10). Relakpsing patient.s (Table II) The PEI remained stable in 5 patients, increased in 5 and decreased in one.
The CFU-L drug sensitivity showed variations when we compared CFU-L inhibition by ara-C and DNR at diagnosis and at relapse. In the same patient, repeat measurements failed to correlate (r -0.4 for 10 6M DNR, r =0.3 for 10 5M DNR; r =0.2 for 10 6M ara-C, r =0.4 for 10 5M a ra-C).
CFU-L sensitivity to DNR (Figure 3 ) remained stable (3 pts) or decreased (6 pts) in the 9 patients who received DNR during maintenance treatment; it remained stable in the 3 other patients who did not. The DI 70 to DNR increased in 4/10 evaluable patients.
The CFU-L inhibition by 10 5M ara-C ( Figure 4 ) decreased dramatically ( -45 + I 1%) in 5 patients despite the absence of ara-C in the maintenance regimen in 2 of them; it remained stable in 3 patients and increased in 2 patients, although all these 5 patients received ara-C during their remission. The DI 50 for this drug increased in 5/11 patients.
The trecatment of relapse was successful using DN R + ara-C or HiDAra-C+AMSA in 6/11 cases, but only one (no. 20) had a longer second remission than the first one. Among patients showing in v,itro CFU-L resistance to at least one drug at time of relapse, only 2 out of 6 entered into remission (in one case after HiDAC+AMSA, one after staindar-d doses ol DNR-ara-C), whereas all the 4 evaluable patients with CFU-L still sensitive to drug entered into CR. 
w: weeks; PEI: number of colonies/I x 104 cells plated. CFU-L growth after continuous exposure to 10-7, 10-6 and 10-5M of ara-C or to 30min exposure to 10-7, 10-6 and 10-M of DNR. Percentage of CFU-L inhibition is given in brackets.
Treatments: TAD: 6-thioguanin, 200 mgm -2 x 7, ara-C 200 mg m -2 x 7, DNR 60 mgm -2 x 3; AML5 of EORTC: adriamycin 50mgm-2 x 1, vincristin mgm-2, Ara-C 160mgm-2 x 7. AML6,7,8 of EORTC: DNR 45mgm-2 dl-d3 (30mgm-2 in AML7), vincristin 1.4mgm-2 d2 (AML6,7), ara-C 200mgm-2 dl-d7; HiDAC+AMSA: ara-C I or 2gm-2x 12+AMSA 12Omgm-2x3 VP16+AMSA=VP16: JOOmgm-2 x 5+AMSA 00mgm -2 x 5. El: Complete resistance with persistence of circulating leukaemic cells without aplasia; E2: failure with leukaemic regrowth; E3: prolonged aplasia with leukaemic regrowth; CR: complete remission. (34) m: months; PEl: number of colonies/l x 104 cells plated. CFU-L growth after continuous exposure to 10 -7, 10 -6 and 10 -M of ara-C or to 30min exposure to 10-7, 10-6 and 10-5M of DNR. Percentage of CFU-L inhibition is given in brackets.
Treatments. AML5 of EORTC: adriamycin 50 mgm -2 x 1, vincristin I mgm-2, ara-C 160 mgm-2 x 7; consolidation: idem, maintenance: either purinethol + 6-mercaptopurine + (DNR + vincristin x 9) + androgen or 6-thioguanin + ara-C immunotherapy. AML6,8 of EORTC: DNR 45 mgm -2 dl-d3, vincristin 1.4 mgm-2 d2 (AML6), ara-C 200 gm -2 dl-d7; consolidation in AML6: idem but DNR dl only. Maintenance for AML6: 6 courses of either DNR+ara-C or AMSA+HiDAC/AMSA+SAZA. AMSA+HidDAC: AMSA 120mgm-2 x 5+ara-C 3gm-2 x4. HiDAC+AMSA: ara-C 1 or 2gm-2 X 12 + AMSA 120 mg m -2 x 3; E2: failure with leukaemic regrowth; E4: toxic death; CR: complete remission.
In our patients, in vitro CFU-L sensitivity to 10-6M DNR was higher in patients entered into CR (73 + 22%) than in resistant patients (55 +41%), but without statistical significance.
Discussion
Repeated study of CFU-L drug sensitivity in 23 patients treated for AML showed different results according to the time of the second study.
In treatment failures, the sensitivity to DNR concentrations used for in vitro-in vivo correlations did not change significantly when tested before and after chemotherapy. In these resistant patients, the interval between the in vitro studies was short (6 weeks), a time probably insufficient to develop a leukaemic clone with properties different than those observed before therapy. These results confirm the preliminary report of McCulloch (1982) , who have repeatedly assessed the self renewal capacity and drug sensitivity of circulating CFU-L: these parameters showed little variation, except evidence of developing drug resistance in a few patients (one relapse and one primary resistance). These data suggested that drug sensitivity and self renewal capacity are heritable characteristics in leukaemic clones, but the small number of patients (7) does not permit definitive conclusions. Treatment failure was predicted by the first in vitro CFU-L sensitivities to DNR but not to ara-C. This superior predictive value of DNR sensitivity was also found in a larger series .
In patients achieving a complete remission, the emergence of a leukamic clone with different properties from that observed at diagnosis was noted at relapse in a majority of cases: the sensitivity to 10-6M DNR or 1-0 M ara-C decreased markedly in 5 patients, increased in one and remained stable in the five others. This can be related to other modifications observed in the study of leukaemic populations in relapse viz. additional chromosomal abnormalities (Pui et al., 1986) , or change in surface phenotype (Borella et al., 1979; Lauer et al., 1982; Pui et al., 1986; Stass et al., 1984) , suggestive of clonal evolution. Schwarzmeier et al. (1984) , using a short term test with 3H uridine incorporation in a whole peripheral blast cell population, also noted an in vitro acquired drug resistance in 2 patients tested repeatedly.
The increase of CFU-L drug resistance observed in several relapsing patients could explain the poor prognosis of AML patients in relapse. The reduction of leukaemic cells during induction treatment and the long time between the two in vitro studies in these patients are in favour of the expansion of a subclone either existing from the beginning of the disease, or selected by mutations in the residual leukaemic clone.
In the great majority of cases, the second CR is shorter than the first one, like in our present study, reflecting a relative chemoresistance, with only moderate cytoreduction during reinduction treatment. Our comparative observations in resistant and relapsing patients are surprising, if one takes into account the good correlation normally observed between in vitro sensitivity of clonogenic cells to DNR+ara-C and clinical response : one could expect, on the contrary, the emergence of in vitro resisting clones after failure of induction treatment and persistence of sensitive clones in most relapsing patients. This could be explained either by the inability of our clonogenic assay to measure leukaemic stem cell properties, or by other resistance mechanisms involving cell kinetic (Raza et al., 1987) or pharmacological factors (Plunkett et al. 1985) . The properties of more primitive leukaemic stem cells could be studied in liquid cultures (Nara & McCulloch, 1985) , and could perhaps better account for the clinical evolution of the disease.
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